Autologous CAR-T cell therapy(Vittoria Biotherapeutics)

N/A

Report date: 2025/06/12 17:08:45

Base Information

Drug NameAutologous CAR-T cell therapy(Vittoria Biotherapeutics)

Drug Alias NameVIPER-101Senza5 CART5VIPER101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsT-cell surface glycoprotein CD5 modulators

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesVittoria Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesVittoria Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A